JUL 13·SEC EDGARLow
Shepard Jay sold (to issuer) 164,472 shares of ESPR
Shepard Jay sold (to issuer) 164,472 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
StockDelisted · Jul 2026NASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$ESPR
Esperion Therapeutics, Inc.
Price · $ESPRvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ESPR in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- — 8 txs
Halladay Benjamin1× · —
10b5-1 plan0%
Top stories · $ESPRMore →
JUL 13·SEC EDGAR
THOMPSON JOHN CRAIG sold (to issuer) 79,873 shares of ESPR
THOMPSON JOHN CRAIG sold (to issuer) 79,873 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
JUL 13·SEC EDGAR
Harlow John B. Jr. sold (to issuer) 424,536 shares of ESPR
Harlow John B. Jr. (Chief Commercial Officer) sold (to issuer) 424,536 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
ESPR sentiment & insider activity
Recent ESPR coverage spans insider activity, mergers & acquisitions and corporate actions.
In the last 30 days, ESPR insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales. The most active reporter was Halladay Benjamin, Chief Financial Officer, with 1 filing.
What's driving ESPR
This is a routine insider sale to the issuer (buyback participation style), with no disclosed price, so it is more a sentiment/positioning signal than a fundamental catalyst.
A director’s sale to the issuer is a routine insider transaction with limited standalone signal, but it can slightly affect sentiment.
Routine insider sale to issuer (buyback participation) with no disclosed price, likely limited incremental signal for near-term fundamentals.
This is a routine insider sale to the issuer, but the disclosed size and CFO role can still affect near-term sentiment.
This is a routine insider sale to the issuer with no disclosed price, so it is unlikely to change fundamentals but can affect near-term sentiment.
alphai scores every news story that mentions ESPR with an AI model for sentiment and relevance, and aggregates insider trades from Esperion Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ESPR
Score
Shepard Jay sold (to issuer) 164,472 shares of ESPR
Shepard Jay sold (to issuer) 164,472 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
1 min readTHOMPSON JOHN CRAIG sold (to issuer) 79,873 shares of ESPR
THOMPSON JOHN CRAIG sold (to issuer) 79,873 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
2 min readHarlow John B. Jr. sold (to issuer) 424,536 shares of ESPR
Harlow John B. Jr. (Chief Commercial Officer) sold (to issuer) 424,536 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
1 min readHalladay Benjamin sold (to issuer) 705,410 shares of ESPR
Halladay Benjamin (Chief Financial Officer) sold (to issuer) 705,410 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
1 min readKoenig Sheldon L. sold (to issuer) 2,121,094 shares of ESPR
Koenig Sheldon L. (President and CEO) sold (to issuer) 2,121,094 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
1 min readEsperion Therapeutics, Inc. (ESPR): Completion of Acquisition or Disposition of Assets
Esperion Therapeutics, Inc. (ESPR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 5 tm2620034d3_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT By and among ESSENCE PARENT INC., ESPERION THERAPEUTICS, INC. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A. acting jointly as, Rights Agent Dated as of July 13, 2026 TABLE
6 min readEsperion Therapeutics, Inc. (ESPR): Submission of Matters to a Vote of Security Holders
Esperion Therapeutics, Inc. (ESPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001434868 0001434868 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readKoenig Sheldon L. sold $169K of ESPR
Koenig Sheldon L. (President and CEO) sold 53,588 shares of Esperion Therapeutics, Inc. (ESPR) at $3.16 ($0.17M total) on 2026-06-17.
1 min read
Esperion Therapeutics (NASDAQ:ESPR) Sees Strong Trading Volume – Here’s What Happened
Esperion Therapeutics (ESPR) saw trading volume rise 31% to 11,491,280 shares on Monday midday, with the stock last at $3.1350. Analyst actions included Needham downgrading to hold and HC Wainwright to neutral; MarketBeat shows an average “Hold” rating and $5.54 target. In its May 8 quarter, EPS was -$0.10 vs -$0.02 expected; revenue was $80.10M vs $84.52M.
4 min read
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization
Esperion Therapeutics has estimated the annual economic burden of heart failure in the U.S. to be $46 billion, encompassing healthcare, medications, and lost productivity. The company advocates for optimizing guideline-directed therapy and enhancing patient education to achieve significant cost savings and improved health outcomes. These strategies are presented as both financially beneficial and life-saving for the healthcare system and society.
2 min read